

Cartilage Oligomeric Matrix Protein Human CHO

Product Data Sheet

Type: Recombinant Cat. No.:

Source: CHO RGB002 (0.1 mg)

Species: Human

Other names: COMP, Thrombospondin-5, TSP5

Description

Total 783 AA. MW: 85.75 kDa (calculated). C-Terminal His-tag+myc-epitope

Introduction to the Molecule

Cartilage oligomeric matrix protein (COMP), also designated thrombospondin 5 (TSP 5), is non-collagenous glycoprotein and is a member of the thrombospondin family of extracellular proteins. COMP is a calcium-binding protein of high molecular weight (>500kDa) present in the extracellular matrix of articular, nasal and tracheal cartilage. COMP is not only cartilage-derived but was found widely in other tissues, including synovium and tendon. Intact COMP is pentameric, with five identical subunits and the carboxy-terminal globular domain of native COMP binds to collagens I, II, and IX. It has been proposed that COMP molecules are important for maintaining the properties and integrity of collagen network. In addition COMP may have a storage and delivery function for hydrophobic cellsignaling molecules such as vitamin D. The significance of COMP for normal development and function of cartilage has been underscored by the discovery that mutations of the COMP gene result in pseudoachondro-plasia and some forms of multiple epiphyseal dysplasia. Most published studies have shown that serum levels of COMP provide important information about metabolic changes occurring in the cartilage matrix in joint disease. These studies describe that serum COMP level correlated with cartilage degradation and is a potential prognostic marker in inflammatory joint diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA). Results have demonstrated an association of increasing serum COMP levels with progressive destruction of articular cartilage monitored radiographically. OA and RA are a common disease causing pain and disability in a significant proportion of the adult population and early diagnostics of these diseases is very important for future therapy.

Research topic

Bone and cartilage metabolism

Amino Acid Sequence

VLLLTLA ALGA	SGQGQS PLGS	SDLGPQM I	LRELQETNAA	LQDVRELLRQ	QVREITFLKN	TVMECDACGM
LLHCAPG FCFP	GVACIQ TESC	GARCGPC F	PAGFTGNGSH	CTDVNECNAH	PCFPRVRCIN	TSPGFRCEAC
LAFAKAN KQVC	TDINEC ETG	QHNCVPN S	SVCINTRGSF	QCGPCQPGFV	GDQASGCQRR	AQRFCPDGSP
DGSRSCV CAVG	WAGNGI LCGF	RDTDLDG F	FPDEKLRCPE	RQCRKDNCVT	VPNSGQEDVD	RDGIGDACDP
CPLVRNP DQRN	TDEDKW GDA	CDNCRSQ K	KNDDQKDTDQ	DGRGDACDDD	IDGDRIRNQA	DNCPRVPNSD
DNCPQKS NPDQ	ADVDHD FVGI	DACDSDQ I	DQDGDGHQDS	RDNCPTVPNS	AQEDSDHDGQ	GDACDDDDDN
PNPGQED ADRD	GVGDVC QDDI	FDADKVV I	DKIDVCPENA	EVTLTDFRAF	QTVVLDPEGD	AQIDPNWVVL
PGLAVGY TAFN	GVDFEG TFHV	UNTVTDD I	DYAGFIFGYQ	DSSSFYVVMW	KQMEQTYWQA	NPFRAVAEPG
EQLRNAL WHTG	DTESQV RLLV	WKDPRNV G	GWKDKKSYRW	FLQHRPQVGY	IRVRFYEGPE	LVADSNVVLD
SQENIIW ANLR	YRCNDT IPEI	OYETARG G	GP EQKLISEE	DL NSAVD HHH	ннн	
	LLHCAPG FCFF LAFAKAN KQVC DGSRSCV CAVG CPLVRNP DQRN DNCPQKS NPDQ PNPGQED ADRD PGLAVGY TAFN EQLRNAL WHTG	LLHCAPG FCFPGVACIQ TESC LAFAKAN KQVCTDINEC ETGC DGSRSCV CAVGWAGNGI LCGH CPLVRNP DQRNTDEDKW GDAC DNCPQKS NPDQADVDHD FVGI PNPGQED ADRDGVGDVC QDDI PGLAVGY TAFNGVDFEG TFHV EQLRNAL WHTGDTESQV RLLW	LLHCAPG FCFPGVACIQ TESGARCGPC I LAFAKAN KQVCTDINEC ETGQHNCVPN S DGSRSCV CAVGWAGNGI LCGRDTDLDG I CPLVRNP DQRNTDEDKW GDACDNCRSQ I DNCPQKS NPDQADVDHD FVGDACDSDQ I PNPGQED ADRDGVGDVC QDDFDADKVV I PGLAVGY TAFNGVDFEG TFHVNTVTDD I EQLRNAL WHTGDTESQV RLLWKDPRNV I	LLHCAPG FCFPGVACIQ TESGARCGPC PAGFTGNGSH LAFAKAN KQVCTDINEC ETGQHNCVPN SVCINTRGSF DGSRSCV CAVGWAGNGI LCGRDTDLDG FPDEKLRCPE CPLVRNP DQRNTDEDKW GDACDNCRSQ KNDDQKDTDQ DNCPQKS NPDQADVDHD FVGDACDSDQ DQDGDGHQDS PNPGQED ADRDGVGDVC QDDFDADKVV DKIDVCPENA PGLAVGY TAFNGVDFEG TFHVNTVTDD DYAGFIFGYQ EQLRNAL WHTGDTESQV RLLWKDPRNV GWKDKKSYRW	LIHCAPG FCFPGVACIQ TESGARCGPC PAGFTGNGSH CTDVNECNAH LAFAKAN KQVCTDINEC ETGQHNCVPN SVCINTRGSF QCGPCQPGFV DGSRSCV CAVGWAGNGI LCGRDTDLDG FPDEKLRCPE RQCRKDNCVT DLVRNP DQRNTDEDKW GDACDNCRSQ KNDDQKDTDQ DGRGDACDDD DNCPQKS NPDQADVDHD FVGDACDSDQ DQDGDGHQDS RDNCPTVPNS PNPGQED ADRDGVGDVC QDDFDADKVV DKIDVCPENA EVTLTDFRAF PGLAVGY TAFNGVDFEG TFHVNTVTDD DYAGFIFGYQ DSSSFYVVMW EQLRNAL WHTGDTESQV RLLWKDPRNV GWKDKKSYRW FLQHRPQVGY	VLLLTLA ALGASGQGQS PLGSDLGPQM LRELQETNAA LQDVRELLRQ QVREITFLKN LLHCAPG FCFPGVACIQ TESGARCGPC PAGFTGNGSH CTDVNECNAH PCFPRVRCIN LAFAKAN KQVCTDINEC ETGQHNCVPN SVCINTRGSF QCGPCQPGFV GDQASGCQRR DGSRSCV CAVGWAGNGI LCGRDTDLDG FPDEKLRCPE RQCRKDNCVT VPNSGQEDVD CPLVRNP DQRNTDEDKW GDACDNCRSQ KNDDQKDTDQ DGRGDACDDD IDGDRIRNQA DNCPQKS NPDQADVDHD FVGDACDSDQ DQDGDGHQDS RDNCPTVPNS AQEDSDHDGQ PNPGQED ADRDGVGDVC QDDFDADKVV DKIDVCPENA EVTLTDFRAF QTVVLDPEGD PGLAVGY TAFNGVDFEG TFHVNTVTDD DYAGFIFGYQ DSSSFYVVMW KQMEQTYWQA EQLRNAL WHTGDTESQV RLLWKDPRNV GWKDKKSYRW FLQHRPQVGY IRVRFYEGPE SQENIIW ANLRYRCNDT IPEDYETARG GPEQKLISEE DLNSAVDHHH HHH

Source

CHO

Formulation

Frozen in production medium.

Reconstitution

Defrost at ambient temperature.

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage, Stability/Shelf Life

Store frozen at -20 °C. Stable until expiry date.

Quality Control Test

SDS-PAGE, ELISA test

Applications

Drug discovery, In vitro diagnostic

Gentaur Molecular Products Voortstraat 49 1910 Kampenhout, Belgium http://www.gentaur-worldwide.com